Biography
Michael Pilo is a capital markets and public company partner in the Firm’s Transactional Practice Group based in New York focusing on capital markets transactions.
Prior to joining Baker McKenzie, Michael worked at leading tech and life sciences law firms as well as the equity capital markets legal groups of bulge bracket investment banks.
Practice Focus
Michael focuses his practice on capital markets transactions across sectors, with particular focus representing issuers and investment banks in life sciences (e.g., biotech, biopharma, medtech, healthcare), technology and crypto, in public and private capital markets deals, including IPOs, high-yield bond offerings, private placements, ATMs, convertible debt and deSPAC business combinations and representing public companies. He regularly counsels public companies, their advisors and boards of directors on securities law compliance, corporate governance practices and disclosure.
Representative Legal Matters
Prior to joining Baker McKenzie, Michael advised on the following matters:
Equity Offerings
- BioAge, a biopharma company targeting the biology of human aging, USD 238 million IPO, USD 11 million concurrent private placement and USD 75 million ATM offering
- Informatica,* a cloud data management tech company, USD 841 million IPO and USD 408 million follow-on offering
- Moderna,* an mRNA medicines biotech company, USD 604.3 million IPO and USD 1.34 billion follow-on offering
- LogicBio Therapeutics, a genetic medicine biotech company, USD 70 million IPO, USD 42 million follow-on offering and USD 50 million ATM offering
- bluebird bio,* a transformative gene therapy biotech company, aggregate of USD 3.1 billion follow-on offerings
- Habit Restaurants, a fast casual company-owned, franchised and licensed restaurant chain, USD 90 million Up-C IPO and USD 155 million secondary follow-on offering
- Surgery Partners, a healthcare services company, USD 270 million IPO
- Sarepta Therapeutics, a biopharma company focused on unique RNA-targeted therapeutics, aggregate of USD 1.5 billion follow-on offerings
- Stoke Therapeutics, an RNA-based medicines biotech company, USD 125 million follow-on offering and USD 150 million ATM offering and exchange offer
- Seres Therapeutics,* a microbiome therapeutics platform company, aggregate of USD 286 million follow-on offerings and aggregate of USD 50 million ATM offerings
- KalVista Pharmaceuticals, a small molecule protease inhibitors biopharma company, aggregate of USD 274 million follow-on offerings, and USD 5 million concurrent private placement
- Change Healthcare,* an independent healthcare technology platform company, USD 640 million Up-C IPO
- nCino,* a tech company providing cloud-based software for financial institutions, USD 250 million IPO
Professional Honors
- Listed, The Legal 500, US Capital Markets: Equity Offerings, 2022-2023
Admissions
- New York~United States
Education
- Brooklyn Law School (JD, cum laude)
- Union College (BS)
Languages
- English
Baker & McKenzie LLP is a Limited Liability Partnership organized under the laws of the State of Illinois (USA) and is a member of Baker & McKenzie International, a Verein organized under the laws of Switzerland.